MB
RGNX icon

MPM BioImpact’s Regenxbio RGNX Stock Holding History

MPM BioImpact’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$525K – 52
2024
Q3 		$525K Sell
50,000
-507,076
-91% -$6.18M 0.08% 42
2024
Q2 		$6.52M Buy
557,076
+7,998
+1% +$124K 1.01% 33
2024
Q1 		$11.6M Hold
549,078
– – 1.86% 18
2023
Q4 		$9.86M Sell
549,078
-107,640
-16% -$1.9M 2.31% 15
2023
Q3 		$10.8M Hold
656,718
– – 2.89% 14
2023
Q2 		$13.1M Buy
656,718
+39,047
+6% +$752K 2.64% 13
2023
Q1 		$11.7M Sell
617,671
-3,701
-0.6% -$81.9K 3.03% 12
2022
Q4 		$14.1M Buy
621,372
+2,289
+0.4% +$51.7K 3.66% 10
2022
Q3 		$16.4M Buy
+619,083
New +$18.4M 3.88% 10

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's RGNX Position: Q4 2024 in Review

MPM BioImpact sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 50,000 shares — an estimated $525K sold.

MPM BioImpact first reported a position in RGNX in Q3 2022 and held it in 9 quarters. The position peaked at $16.4M in Q3 2022. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

  • MPM BioImpact reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
  • MPM BioImpact sold 50,000 Regenxbio shares in Q4 2024, an estimated $525K.
  • MPM BioImpact first reported a position in Regenxbio in Q3 2022 and held it in 9 quarters.
  • MPM BioImpact's Regenxbio position peaked at $16.4M in Q3 2022.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.